Lexicon Pharmaceuticals Company Insiders
| LXRX Stock | USD 1.60 0.01 0.62% |
Lexicon Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Lexicon Pharmaceuticals suggests that vertually all insiders are extremely bullish. Lexicon Pharmaceuticals employs about 285 people. The company is managed by 31 executives with a total tenure of roughly 232 years, averaging almost 7.0 years of service per executive, having 9.19 employees per reported executive.
| Lonnel Coats CEO CEO and President and Director |
| Raymond Debbane Chairman Independent Chairman of the Board |
Lexicon Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-11-16 | Lonnel Coats | Acquired 90000 @ 1.05 | View | ||
| 2023-11-10 | Lonnel Coats | Acquired 10000 @ 1.01 | View | ||
| 2023-10-12 | Raymond Debbane | Acquired 148820 @ 1.03 | View | ||
| 2023-10-10 | Raymond Debbane | Acquired 508306 @ 1.14 | View | ||
| 2023-09-14 | Jeffrey L Wade | Acquired 10000 @ 1.38 | View | ||
| 2023-08-04 | Wendy Mcdermott | Acquired 6000 @ 1.84 | View | ||
| 2023-06-29 | Lonnel Coats | Acquired 10000 @ 2.16 | View | ||
| 2023-06-26 | Lonnel Coats | Acquired 10000 @ 2.18 | View | ||
| 2023-06-23 | Wendy Mcdermott | Acquired 10000 @ 2.43 | View | ||
| 2023-06-22 | Lonnel Coats | Acquired 40000 @ 2.31 | View | ||
| 2023-06-20 | Jeffrey L Wade | Acquired 12000 @ 2.33 | View | ||
| 2023-06-05 | International S.C.A. Artal | Acquired 27775050 @ 2.6 | View |
Monitoring Lexicon Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Lexicon |
Lexicon Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.5067) % which means that it has lost $0.5067 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.685) %, meaning that it created substantial loss on money invested by shareholders. Lexicon Pharmaceuticals' management efficiency ratios could be used to measure how well Lexicon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.91 in 2024. Return On Capital Employed is likely to rise to -0.82 in 2024. At this time, Lexicon Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 104.9 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 786.6 K in 2024.Common Stock Shares Outstanding is likely to rise to about 232.2 M in 2024, whereas Net Loss is likely to drop (123.1 M) in 2024.
Lexicon Pharmaceuticals Workforce Comparison
Lexicon Pharmaceuticals is rated second overall in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 2,091. Lexicon Pharmaceuticals retains roughly 285 in number of employees claiming about 14% of equities under Health Care industry.
Lexicon Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexicon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexicon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lexicon Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lexicon Pharmaceuticals Notable Stakeholders
A Lexicon Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lexicon Pharmaceuticals often face trade-offs trying to please all of them. Lexicon Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lexicon Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lonnel Coats | CEO and President and Director | Profile | |
| Raymond Debbane | Independent Chairman of the Board | Profile | |
| Praveen Tyle | Executive Vice President of Research and Development | Profile | |
| Gary Branch | Vice President - Sales | Profile | |
| Pablo Lapuerta | Executive Vice President - Clinical Development, Chief Medical Officer | Profile | |
| James Tessmer | Vice President - Finance & Accounting | Profile | |
| Jeffrey Wade | CFO, Executive Vice President - Corporate Development | Profile | |
| Kiernan Seth | Vice President - Marketing | Profile | |
| Jeffrey JD | President CFO | Profile | |
| Alan Main | Executive VP of CMC and Supply Operations | Profile | |
| Robert Lefkowitz | Independent Director | Profile | |
| Christopher Sobecki | Independent Director | Profile | |
| Alan Nies | Independent Director | Profile | |
| Frank Palantoni | Independent Director | Profile | |
| Judith Swain | Independent Director | Profile | |
| Philippe Amouyal | Independent Director | Profile | |
| Samuel Barker | Independent Director | Profile | |
| Brian Crum | General VP | Profile | |
| John Northcott | VP of Marketing, Commercial Strategy and Operations | Profile | |
| Chas Schultz | Executive Advocacy | Profile | |
| Robert MD | Consultant Director | Profile | |
| Desiree Gendron | Vice Training | Profile | |
| Dixon Terry | Vice Compliance | Profile | |
| Carrie Siragusa | Vice Marketing | Profile | |
| Alexander Santini | Chief Commercial Officer | Profile | |
| Lisa DeFrancesco | Head Strategy | Profile | |
| Kenneth MD | Senior Assurance | Profile | |
| Tom Garner | Senior Officer | Profile | |
| Mike Kelly | Investor Officer | Profile | |
| Kristen Alexander | Vice Accounting | Profile | |
| Wendy McDermott | Vice Resources | Profile |
About Lexicon Pharmaceuticals Management Performance
The success or failure of an entity such as Lexicon Pharmaceuticals often depends on how effective the management is. Lexicon Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lexicon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lexicon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.96) | (0.91) | |
| Return On Capital Employed | (0.87) | (0.82) | |
| Return On Assets | (0.77) | (0.73) | |
| Return On Equity | (1.90) | (1.81) |
The data published in Lexicon Pharmaceuticals' official financial statements usually reflect Lexicon Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lexicon Pharmaceuticals. For example, before you start analyzing numbers published by Lexicon accountants, it's critical to develop an understanding of what Lexicon Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Lexicon Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lexicon Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lexicon Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lexicon Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Lexicon Pharmaceuticals' management manipulating its earnings.
Lexicon Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Lexicon Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lexicon Pharmaceuticals within its industry.Lexicon Pharmaceuticals Manpower Efficiency
Return on Lexicon Pharmaceuticals Manpower
| Revenue Per Employee | 4.2K | |
| Revenue Per Executive | 38.8K | |
| Net Loss Per Employee | 621.5K | |
| Net Loss Per Executive | 5.7M | |
| Working Capital Per Employee | 508.8K | |
| Working Capital Per Executive | 4.7M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Lexicon Stock analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.80) | Revenue Per Share 0.005 | Quarterly Revenue Growth 24.071 | Return On Assets (0.51) |
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.